[{"id":"9d2b54f0-0907-4b8a-b5db-69cd00d54eb2","acronym":"SWOG S1608","url":"https://clinicaltrials.gov/study/NCT03269669","created_at":"2021-01-29T07:15:29.475Z","updated_at":"2025-02-25T12:26:46.064Z","phase":"Phase 2","brief_title":"Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma","source_id_and_acronym":"NCT03269669 - SWOG S1608","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • doxorubicin hydrochloride • Gazyva (obinutuzumab) • cyclophosphamide • vincristine • prednisone • bendamustine • Ukoniq (umbralisib) • Belrapzo (bendamustine RTD) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 01/23/2018","start_date":" 01/23/2018","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-24"},{"id":"722e7e39-2b2e-4e81-be40-58b1e321be96","acronym":"","url":"https://clinicaltrials.gov/study/NCT06043713","created_at":"2023-09-21T15:10:30.740Z","updated_at":"2025-02-25T13:41:44.027Z","phase":"Phase 1","brief_title":"Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations","source_id_and_acronym":"NCT06043713","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HER-2 • KRAS • BRAF • ALK • TMB • MSI • NTRK","pipe":" | ","alterations":" KRAS mutation • TMB-H • BRAF mutation • HER-2 amplification • ROS1 fusion • KRAS G12 • NTRK fusion","tags":["HER-2 • KRAS • BRAF • ALK • TMB • MSI • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • TMB-H • BRAF mutation • HER-2 amplification • ROS1 fusion • KRAS G12 • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • bendamustine • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 5","initiation":"Initiation: 12/15/2023","start_date":" 12/15/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 02/09/2026","study_completion_date":" 02/09/2026","last_update_posted":"2025-02-21"},{"id":"4ba4b07b-a4a4-4a2f-83be-8b39ce10d97d","acronym":"OLYMPIA-1","url":"https://clinicaltrials.gov/study/NCT06091254","created_at":"2023-10-19T17:13:09.646Z","updated_at":"2025-02-25T14:03:56.559Z","phase":"Phase 3","brief_title":"A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma","source_id_and_acronym":"NCT06091254 - OLYMPIA-1","lead_sponsor":"Regeneron Pharmaceuticals","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • bendamustine • Ordspono (odronextamab)"],"overall_status":"Recruiting","enrollment":" Enrollment 478","initiation":"Initiation: 12/12/2023","start_date":" 12/12/2023","primary_txt":" Primary completion: 04/04/2029","primary_completion_date":" 04/04/2029","study_txt":" Completion: 04/04/2029","study_completion_date":" 04/04/2029","last_update_posted":"2025-02-19"},{"id":"c70f6861-a666-4861-ad3d-2301e394ab62","acronym":"ASCEND","url":"https://clinicaltrials.gov/study/NCT02970318","created_at":"2021-01-17T17:36:01.594Z","updated_at":"2025-02-25T14:01:11.516Z","phase":"Phase 3","brief_title":"A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL","source_id_and_acronym":"NCT02970318 - ASCEND","lead_sponsor":"Acerta Pharma BV","biomarkers":" CD5 • FCER2","pipe":" | ","alterations":" CD20 positive","tags":["CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Calquence (acalabrutinib) • Zydelig (idelalisib) • bendamustine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 310","initiation":"Initiation: 02/02/2017","start_date":" 02/02/2017","primary_txt":" Primary completion: 09/03/2021","primary_completion_date":" 09/03/2021","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2025-02-19"},{"id":"d02f7b2d-1c37-4780-a6b7-7db1aff0b46d","acronym":"PBCAR0191-01","url":"https://clinicaltrials.gov/study/NCT03666000","created_at":"2021-01-18T17:59:15.398Z","updated_at":"2025-02-25T15:10:55.408Z","phase":"Phase 1","brief_title":"Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients with R/r NHL and R/r B-cell ALL","source_id_and_acronym":"NCT03666000 - PBCAR0191-01","lead_sponsor":"Imugene Limited","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • bendamustine • fludarabine IV • azercabtagene zapreleucel (PBCAR0191) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 129","initiation":"Initiation: 03/11/2019","start_date":" 03/11/2019","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-13"},{"id":"33ca6a18-d45b-42c8-9bb0-e546b4b79d4d","acronym":"GLOBRYTE","url":"https://clinicaltrials.gov/study/NCT06084936","created_at":"2023-10-16T15:12:59.101Z","updated_at":"2025-02-25T16:33:44.879Z","phase":"Phase 3","brief_title":"A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma","source_id_and_acronym":"NCT06084936 - GLOBRYTE","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CCND1","pipe":" | ","alterations":" Chr t(11;14)","tags":["CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • Gazyva (obinutuzumab) • bendamustine • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm)"],"overall_status":"Recruiting","enrollment":" Enrollment 182","initiation":"Initiation: 10/22/2023","start_date":" 10/22/2023","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-02-07"},{"id":"3a5c5d6a-237c-4943-9f23-41234e0aa377","acronym":"","url":"https://clinicaltrials.gov/study/NCT03755804","created_at":"2021-01-18T18:27:48.805Z","updated_at":"2025-02-25T16:37:17.115Z","phase":"Phase 2","brief_title":"Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17","source_id_and_acronym":"NCT03755804","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • vincristine • prednisone • dacarbazine • bendamustine • bleomycin • vinblastine • Neupogen (filgrastim) • cyclophosphamide intravenous • prednisolone"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 12/12/2018","start_date":" 12/12/2018","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-07"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"3615e982-327f-4793-b8ff-fdb95f9f33a8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03856216","created_at":"2021-01-18T19:01:48.041Z","updated_at":"2025-02-25T16:52:26.547Z","phase":"Phase 2","brief_title":"Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation","source_id_and_acronym":"NCT03856216","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD22 • HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["CD22 • HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • methotrexate • Besponsa (inotuzumab ozogamicin) • bendamustine • melphalan • Truxima (rituximab-abbs) • fludarabine IV • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Neupogen (filgrastim) • Novex (rituximab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 10/28/2019","start_date":" 10/28/2019","primary_txt":" Primary completion: 03/31/2027","primary_completion_date":" 03/31/2027","study_txt":" Completion: 03/31/2027","study_completion_date":" 03/31/2027","last_update_posted":"2025-02-04"},{"id":"c2530d5f-2067-4089-83d8-8b338ff98d19","acronym":"","url":"https://clinicaltrials.gov/study/NCT06245629","created_at":"2025-02-26T11:14:39.219Z","updated_at":"2025-02-26T11:14:39.219Z","phase":"","brief_title":"Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma","source_id_and_acronym":"NCT06245629","lead_sponsor":"Uppsala University","biomarkers":" SLC1A5","pipe":"","alterations":" ","tags":["SLC1A5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • bendamustine • melphalan"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/24/2024","start_date":" 11/24/2024","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-11-28"},{"id":"23dbac8b-ecfd-4311-9f6c-4354922bc4b0","acronym":"RELEVANCEt","url":"https://clinicaltrials.gov/study/NCT01650701","created_at":"2021-01-18T07:06:43.879Z","updated_at":"2025-02-25T14:33:35.027Z","phase":"Phase 3","brief_title":"A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma","source_id_and_acronym":"NCT01650701 - RELEVANCEt","lead_sponsor":"The Lymphoma Academic Research Organisation","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • bendamustine"],"overall_status":"Completed","enrollment":" Enrollment 1030","initiation":"Initiation: 02/01/2012","start_date":" 02/01/2012","primary_txt":" Primary completion: 05/31/2017","primary_completion_date":" 05/31/2017","study_txt":" Completion: 04/30/2024","study_completion_date":" 04/30/2024","last_update_posted":"2024-10-09"},{"id":"879fd467-51b3-46e4-9863-a9475f8f4f72","acronym":"Oracle","url":"https://clinicaltrials.gov/study/NCT03593018","created_at":"2021-01-18T17:39:39.095Z","updated_at":"2025-02-25T14:27:18.930Z","phase":"Phase 3","brief_title":"Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL","source_id_and_acronym":"NCT03593018 - Oracle","lead_sponsor":"The Lymphoma Academic Research Organisation","biomarkers":" PD-1 • BCL6 • CXCL13 • ICOS • MME","pipe":" | ","alterations":" PD-1 expression","tags":["PD-1 • BCL6 • CXCL13 • ICOS • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • azacitidine • bendamustine • Istodax (romidepsin) • Onureg (azacitidine oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 86","initiation":"Initiation: 11/09/2018","start_date":" 11/09/2018","primary_txt":" Primary completion: 02/10/2021","primary_completion_date":" 02/10/2021","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-10-09"},{"id":"c3e37946-e4b9-4544-a60c-995c415bbbe7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06563778","created_at":"2025-02-26T10:28:05.577Z","updated_at":"2025-02-26T10:28:05.577Z","phase":"Phase 2","brief_title":"Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.","source_id_and_acronym":"NCT06563778","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" PD-1","pipe":"","alterations":" ","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e decitabine • Adcetris (brentuximab vedotin) • Epidaza (chidamide) • bendamustine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/01/2024","start_date":" 09/01/2024","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2024-08-21"},{"id":"ccaab729-08e3-4b0f-ae17-a92ba3b288af","acronym":"","url":"https://clinicaltrials.gov/study/NCT02996773","created_at":"2021-01-18T14:44:29.668Z","updated_at":"2025-02-25T16:24:52.034Z","phase":"Phase 1","brief_title":"Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine","source_id_and_acronym":"NCT02996773","lead_sponsor":"University of Arizona","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • bendamustine • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/29/2016","start_date":" 11/29/2016","primary_txt":" Primary completion: 08/25/2025","primary_completion_date":" 08/25/2025","study_txt":" Completion: 08/25/2025","study_completion_date":" 08/25/2025","last_update_posted":"2024-07-11"},{"id":"63e0d60a-e16f-4451-bd50-7c30a33e2a8d","acronym":"BELLWAVE-008","url":"https://clinicaltrials.gov/study/NCT05624554","created_at":"2022-11-22T15:58:55.794Z","updated_at":"2024-07-02T16:34:25.934Z","phase":"Phase 3","brief_title":"A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)","source_id_and_acronym":"NCT05624554 - BELLWAVE-008","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" TP53 • IGH","pipe":" | ","alterations":" IGH mutation","tags":["TP53 • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IGH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • bendamustine • Truxima (rituximab-abbs) • fludarabine IV • nemtabrutinib (MK-1026)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 03/16/2023","start_date":" 03/16/2023","primary_txt":" Primary completion: 05/19/2027","primary_completion_date":" 05/19/2027","study_txt":" Completion: 03/17/2031","study_completion_date":" 03/17/2031","last_update_posted":"2024-06-14"},{"id":"5dee7c2d-c458-4efc-8ddb-50ee403de9bf","acronym":"SGN35-015","url":"https://clinicaltrials.gov/study/NCT01716806","created_at":"2021-01-18T07:28:55.529Z","updated_at":"2024-07-02T16:34:27.249Z","phase":"Phase 2","brief_title":"A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)","source_id_and_acronym":"NCT01716806 - SGN35-015","lead_sponsor":"Seagen Inc.","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Adcetris (brentuximab vedotin) • dacarbazine • bendamustine"],"overall_status":"Completed","enrollment":" Enrollment 131","initiation":"Initiation: 10/31/2012","start_date":" 10/31/2012","primary_txt":" Primary completion: 04/07/2023","primary_completion_date":" 04/07/2023","study_txt":" Completion: 09/12/2023","study_completion_date":" 09/12/2023","last_update_posted":"2024-06-11"},{"id":"6f307756-0908-4621-b9f3-65923112cc09","acronym":"SHINE ","url":"https://clinicaltrials.gov/study/NCT01776840","created_at":"2021-01-18T07:50:07.776Z","updated_at":"2024-07-02T16:34:37.245Z","phase":"Phase 3","brief_title":"A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma","source_id_and_acronym":"NCT01776840 - SHINE ","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" CD20 • CCND1 • PAX5 • CD5","pipe":" | ","alterations":" Chr t(11;14) • CCND1 expression","tags":["CD20 • CCND1 • PAX5 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • bendamustine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 523","initiation":"Initiation: 05/01/2013","start_date":" 05/01/2013","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-06-07"},{"id":"8de268c6-da6c-4e99-84fd-668feff0456e","acronym":"ALLIANCE A041202","url":"https://clinicaltrials.gov/study/NCT01886872","created_at":"2021-01-17T17:18:59.159Z","updated_at":"2024-07-02T16:34:37.292Z","phase":"Phase 3","brief_title":"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT01886872 - ALLIANCE A041202","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD4 • CD5 • FCER2","pipe":" | ","alterations":" Chr t(11;14)","tags":["CD20 • CD4 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • bendamustine • Truxima (rituximab-abbs) • Belrapzo (bendamustine RTD) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 547","initiation":"Initiation: 12/09/2013","start_date":" 12/09/2013","primary_txt":" Primary completion: 08/07/2018","primary_completion_date":" 08/07/2018","study_txt":" Completion: 01/30/2025","study_completion_date":" 01/30/2025","last_update_posted":"2024-06-07"},{"id":"24c91644-22bc-4249-aaa6-106bdc7c0471","acronym":"","url":"https://clinicaltrials.gov/study/NCT03524235","created_at":"2021-01-18T17:21:46.884Z","updated_at":"2024-07-02T16:34:59.315Z","phase":"Phase 1","brief_title":"Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL","source_id_and_acronym":"NCT03524235","lead_sponsor":"Noah Merin","biomarkers":" MYC • CD20 • HLA-DRB1 • CD4 • HLA-DQB1 • HLA-B","pipe":" | ","alterations":" Chr del(17p) • Chr del(11q) • Chr t(4;14) • Chr t(14;16) • CD20 expression","tags":["MYC • CD20 • HLA-DRB1 • CD4 • HLA-DQB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(17p) • Chr del(11q) • Chr t(4;14) • Chr t(14;16) • CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bendamustine • fludarabine IV • Belrapzo (bendamustine RTD)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/18/2018","start_date":" 07/18/2018","primary_txt":" Primary completion: 11/07/2021","primary_completion_date":" 11/07/2021","study_txt":" Completion: 11/01/2031","study_completion_date":" 11/01/2031","last_update_posted":"2024-06-04"},{"id":"89d85ce4-ea03-4058-ba7a-82fb284611ca","acronym":"EPCORE NHL-2","url":"https://clinicaltrials.gov/study/NCT04663347","created_at":"2021-06-15T19:53:31.777Z","updated_at":"2024-07-02T16:34:59.645Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","source_id_and_acronym":"NCT04663347 - EPCORE NHL-2","lead_sponsor":"Genmab","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • lenalidomide • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • vincristine • prednisone • dexamethasone • bendamustine • Epkinly (epcoritamab-bysp)"],"overall_status":"Recruiting","enrollment":" Enrollment 662","initiation":"Initiation: 11/03/2020","start_date":" 11/03/2020","primary_txt":" Primary completion: 03/31/2029","primary_completion_date":" 03/31/2029","study_txt":" Completion: 03/31/2029","study_completion_date":" 03/31/2029","last_update_posted":"2024-05-31"},{"id":"adf70f50-0fc0-4474-a764-ea766f835694","acronym":"","url":"https://clinicaltrials.gov/study/NCT01286272","created_at":"2021-01-18T05:13:11.418Z","updated_at":"2024-07-02T16:35:02.742Z","phase":"Phase 2","brief_title":"Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT01286272","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • CD4","pipe":"","alterations":" ","tags":["BCL2 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • bendamustine • Arzerra (ofatumumab) • Belrapzo (bendamustine RTD)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 135","initiation":"Initiation: 04/08/2011","start_date":" 04/08/2011","primary_txt":" Primary completion: 05/24/2017","primary_completion_date":" 05/24/2017","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2024-05-17"},{"id":"15ee9486-9dcc-4c8c-8158-5823809b90ac","acronym":"FluBuBe","url":"https://clinicaltrials.gov/study/NCT04942730","created_at":"2021-06-28T17:52:48.047Z","updated_at":"2024-07-02T16:35:05.320Z","phase":"Phase 2","brief_title":"Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)","source_id_and_acronym":"NCT04942730 - FluBuBe","lead_sponsor":"St. Petersburg State Pavlov Medical University","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • bendamustine • fludarabine IV • busulfan • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 01/21/2021","start_date":" 01/21/2021","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 04/30/2024","study_completion_date":" 04/30/2024","last_update_posted":"2024-05-07"},{"id":"cb6b89eb-4f9f-4788-a9df-5a300e0272bd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04049825","created_at":"2021-01-18T19:51:38.271Z","updated_at":"2024-07-02T16:35:06.344Z","phase":"Phase 1","brief_title":"A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL","source_id_and_acronym":"NCT04049825","lead_sponsor":"Otsuka Pharmaceutical Co., Ltd.","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bendamustine • OPB-111077"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 11/22/2019","start_date":" 11/22/2019","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-05-02"},{"id":"a2dce45d-64bf-4128-876e-4a25b3b1a037","acronym":"","url":"https://clinicaltrials.gov/study/NCT01059786","created_at":"2021-01-18T04:10:26.425Z","updated_at":"2024-07-02T16:35:06.574Z","phase":"Phase 2","brief_title":"Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia","source_id_and_acronym":"NCT01059786","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD22 • IL2RA • ITGAE • ITGAX • ISG20","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • CD22 • IL2RA • ITGAE • ITGAX • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bendamustine • pentostatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 69","initiation":"Initiation: 07/01/2010","start_date":" 07/01/2010","primary_txt":" Primary completion: 12/15/2022","primary_completion_date":" 12/15/2022","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-01"}]